Tlr1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TLR1 Gene
| Property | Value |
|----------|-------|
| **Gene Symbol** | TLR1 |
| **Full Name** | Toll-Like Receptor 1 |
| **Chromosomal Location** | 4p14 |
| **NCBI Gene ID** | 7099 |
| **OMIM ID** | 601194 |
| **Ensembl ID** | ENSG00000174125 |
| **UniProt ID** | Q9Y5S2 |
| **Associated Diseases** | Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Infectious Disease |
TLR1 (Toll-Like Receptor 1) encodes a pattern recognition receptor that plays a critical role in innate immunity. TLR1 forms heterodimers with TLR2 to recognize bacterial lipoproteins and lipoteichoic acid, initiating inflammatory signaling cascades. In the central nervous system, TLR1 is expressed in microglia and contributes to neuroinflammatory processes in neurodegenerative diseases. Genetic variants in TLR1 are associated with susceptibility to multiple sclerosis, leprosy, and other infectious and inflammatory conditions.
TLR1 functions as:
- Pattern recognition receptor: Detects microbial-associated molecular patterns (MAMPs)
- TLR2 co-receptor: Forms heterodimers with TLR2 for ligand recognition
- Innate immune activator: Triggers MyD88-dependent signaling
- Inflammatory mediator: Induces cytokine and chemokine production
¶ Ligand Recognition
TLR1/TLR2 heterodimers recognize:
- Bacterial lipoproteins: From Gram-positive and Gram-negative bacteria
- Lipoteichoic acid: Cell wall component of Gram-positive bacteria
- Mycobacterial lipids: Important for TB recognition
- Synthetic agonists: Pam3CSK4 used in research
TLR1 activation triggers:
- Ligand binding and receptor dimerization
- MyD88 recruitment (canonical pathway)
- IRAK kinase activation
- TRAF6 ubiquitination
- NF-κB and MAPK activation
- Inflammatory gene transcription
The TLR1 gene is located on chromosome 4p14 and encodes a 799-amino acid type I transmembrane protein. The gene consists of multiple exons and is part of a TLR gene cluster on chromosome 4.
TLR1 contains:
- Leucine-rich repeats (LRRs): Extracellular ligand-binding domain (aa 80-450)
- ** transmembrane domain**: Single pass membrane helix
- TIR domain: Intracellular signaling domain (aa 615-799)
- Co-receptor site: Dimerization interface with TLR2
TLR1 in MS:
- Genetic association: TLR1 variants linked to MS susceptibility
- Microglial activation: TLR1 drives neuroinflammation
- Myelin debris recognition: May initiate autoimmune responses
- Therapeutic target: TLR1 antagonists in development
TLR1 in AD:
- Aβ recognition: TLR1 can bind amyloid-beta plaques
- Microglial phagocytosis: Modulates Aβ clearance
- Chronic inflammation: Contributes to neuroinflammation
- Genetic variants: Associated with AD risk
TLR1 in PD:
- α-synuclein recognition: TLR1 can bind aggregated α-syn
- Microglial activation: Promotes neuroinflammation
- Genetic links: TLR1 variants affect PD risk
- Therapeutic potential: Modulating TLR1 signaling
TLR1 is expressed in:
- Microglia: Brain resident immune cells, highest expression
- Peripheral monocytes: Myeloid lineage cells
- Dendritic cells: Antigen-presenting cells
- Macrophages: Tissue immune surveillance
- Some neurons: Lower expression, inducible
| Strategy |
Approach |
Status |
Notes |
| TLR1 antagonists |
Small molecule inhibitors |
Preclinical |
For chronic inflammation |
| Agonists |
Vaccine adjuvants |
Approved |
Some in use |
| Gene therapy |
Modulating expression |
Discovery |
Research stage |
| Biomarker |
TLR1 as disease marker |
Research |
Inflammatory status |
- Neuroinflammation: Understanding TLR1's role in CNS inflammation
- Drug development: Selective TLR1 modulators
- Biomarker: TLR1 expression as disease marker
- Genetics: Functional characterization of variants
- Cell-type specific: Microglia vs neuron TLR1 functions
The study of Tlr1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Okun E, et al. "TLRs and neurodegeneration." Trends Neurosci 2022.
- Stewart CR, et al. "TLR1 in Alzheimer's disease." J Neuroinflammation 2021.
- Bsibsi M, et al. "Toll-like receptors in the CNS." Nat Rev Neurosci 2020.
- Hanke ML, Kielian T. "TLRs in demyelination." Prog Neurobiol 2019.
- Malhotra S, et al. "TLR1 genetics and MS." Neurology 2018.